The Roche Group reported sales of CHF 62.8 billion ($68.12 billion) in 2021, a rise of 8% from a year earlier and largely driven by brisk demand for its Covid-19-related diagnostic products. Diagnostic sales increased by 29% during the year. By contrast, the pharmaceutical division, which accounts for 72% of group turnover, reported a sales increase of just 1%. Measured in constant exchange rates, this increase was 3%.
